Innovation Pharmaceuticals, a renowned biopharmaceutical firm operating in the healthcare fraternity has recently announced that it has signed a drug supply contract with Evonik Corporation, a global leader in the bulk & specialty chemicals industry. Reportedly, Innovation Pharmaceuticals aims to mass produce its commercial-grade Brilacidin with Evonik’s support for its drug supply.
Arthur P. Bertolino, Chief Medical Officer (CMO) at Innovation Pharmaceuticals commented that integrating Evonik’s expertise to CMC’s efforts will in turn help the company in rapidly moving its Brilacidin programs toward the finish line. He further added that the company anticipates the drug substance to be manufactured to high quality standards that aid the company in upholding its long-term needs across several anchored clinical indications around the Brilacidin Franchise.
For the record, Brilacidin is a versatile drug candidate with exclusive and robust anti-inflammatory, antibacterial, and immunomodulatory properties. The compound exhibiting wide scale therapeutic potential has been successfully tested in clinical trials of serious skin infections, ulcerative proctitis/ulcerative proctosigmoiditis, and oral mucositis.
Reports reveal that the Phase 2 trial of Brilacidin-OM has successfully met its primary and secondary endpoints that include reducing the incidence of Severe Oral Mucositis (SOM) in patients. The drug also showed positive results in a Phase 2 Proof-of-Concept trial.
Dr. Andreas Meudt, VP, Product Line Exclusive Synthesis at Evonik’s Health Care Business Line, reported that the company is pleased to work with Innovation Pharmaceuticals and is looking forward to significantly scale up & industrialize the production of the Brilacidin drug.
Industry experts deem that with Innovation Pharmaceuticals securing the drug supply contract through a major Contract Development and Manufacturing Organization, such as Evonik, it is likely to fast-track the drug deployment toward providing the much-needed treatments to patients.
For the record, Evonik, the specialty chemicals industry major is active in more than 100 countries worldwide and has generated sales of worth €14.4 billion in the fiscal year 2017.
